Fady Iskander MD, MSc

1/8 🚨 The results of CLOSURE-AF are in, providing a sobering look at Left Atrial Appendage Closure (LAAC). This was the first trial to test the device against modern DOAC therapy in the high-risk patients seen in daily practice. The verdict: LAAC failed to meet non-inferiority

JUST OUT #JACCINT @JACCJournals . SOTA comprehensive review on #PVL diagnosis and management post #TAVR. jacc.org/doi/full/10.10…

JUST OUT! Our official "Double-tap" Sapien 3 Ultra Resilia #TAVR paper is here #JACCINT @JACCJournals, showing double-tap post-dilatation optimizes S3UR expansion on fluoro. This has now become standard practice @MountSinaiHeart and many centers worldwide! Nice editorial by @ronwaksman and Viewpoints by the #Vancouver group! jacc.org/doi/10.1016/j.… jacc.org/doi/10.1016/j.… jacc.org/doi/10.1016/j.… @MountSinaiNYC @IcahnMountSinai @ParasuramMD @DoctorKini @KHERA_MD @LucySafi @sunnygoelmd @AmithoodaMD @georgedangas @DrDavidReich @Dr_BrendanCarr @DLBHATTMD

6 yrs after surgery or #TAVR with CoreValve/Evolut, low-risk AS pts showed no difference in all-cause mortality or disabling #stroke in the Evolut Low-Risk trial. However, reinterventions were higher after TAVR, largely driven by increased AR. jacc.org/doi/10.1016/j.… #JACC

JUST OUT #JACCINT @JACCJournals ! Our Redo #TAVR concept and planning simplified. Coronary Risk Zone (CRZ) denotes the zone that you MUST measure the valve to coronary/aorta/STJ distance to assess coronary obstruction risk. The minimal distance is what matter most. Great work by @OleDeBacker @bapat_savrtavr @Miho_Fukui_ @SyedZaid to help move this field forward! jacc.org/doi/10.1016/j.…

Bicuspid is no longer a niche. In this SOTA, @didier_tchetche et al walk through TAVI in BAV: phenotypes, CT sizing (BAVARD, circle, CASPER), procedural tricks, long-term concerns and the need for TAVI vs SAVR RCTs. Don't miss it 👉eurointervention.pcronline.com/article/transc… #TAVI #cardiotwitter #CardioX #CardioEd @YWillemen @Vinscesario

Word class conference! Looking forward to it!

IV #thrombolysis 4.5–24h post-stroke improves outcomes but increases sICH risk. Tenecteplase ≈ Alteplase, with less bleeding trend. #Stroke @amirghabousian @AlimoradiMD @fady_iskander @azeemlatib @ToshikiKuno @RamchandPreethi ahajournals.org/doi/10.1161/ci…

Transapical UNICORN to facilitate valve in valve TAVR. @MCWcardiology onlinelibrary.wiley.com/share/author/S…

Transcatheter Valve Replacement in Adults with Congenital Heart Disease. Is there limited prothesis longevity in this patient population? @EleidMack @Dr_JHAnderson ahajrnls.org/4nB5mzo

Fresh update on cardiovascular salaries.

@AhmadAlkhalilMD Thanks Ahmad!

@fady_iskander Great case and nice result!

AVP II placement for severe PVL with successful reduction to trivial PVL. #CMPG structural heart

Sub-analysis of the BEST trial showing IVUS-guided PCI equivalent to CABG! An excellent review of the paper by @GreggWStone discussed how we can be better at what we do and be equivalent to bypass. In the order of importance, just in my opinion! 1-Intravscular imaging. A must, not an option. Needs meaningful use not just "use" 2-Complete revascularization- I am a huge believer. Complete the job 3-Physiology! will leave it to physiology enthusiasts :D heart.bmj.com/content/111/19… heart.bmj.com/content/111/19… #cardioX

The OPTION-STEMI trial, presented at #ESCCongress2025, investigated the timing of complete revascularization in patients with STEMI and multivessel disease. 🥸 See below for some contrast with the SLIM clinical trial (note cohorts are STEMI vs. NSTEMI) 😱see below 👇👇👇

Early Discontinuation of Aspirin after PCI in Low-Risk Acute Myocardial Infarction: @NEJM 🥸 Will the use of Aspirin decline overtime in ACS management? #ESCCongress2025 😱The TARGET-FIRST trial 👇👇👇

2025 ESC/EACTS Guidelines for the management of valvular heart disease: @ESC_Journals 🥸Few highlights - dense document, please read full document for details. 😱 Summary 👇👇👇

The 2025 ESC/EACTS guidelines on the management of valvular heart disease have just been released, with an important update: the age threshold for the Heart Team to consider TAVI instead of surgical intervention has been lowered from 75 to 70 years in patients with tricuspid aortic valve anatomy deemed suitable. #ESCCongress academic.oup.com/eurheartj/adva…